Market research
CYTH Cyclo Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 24M
- P/E ratio
- Not available
- Analyst target
- 0.95
- Dividend yield
- Not available
- Beta
- -0.57
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US23254X2018
- Market cap
- 24M
- P/E ratio
- Not available
- Analyst target
- 0.95
- Dividend yield
- Not available
- Beta
- -0.57
About
About Cyclo Therapeutics Inc
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida. Cyclo Therapeutics, Inc. is a subsidiary of Rafael Holdings, Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CYTH discussion.
5 years, 4 months ago
From a valuation standpoint, the stock is 98.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 15.2.
Based on the above factors, Cyclo Therapeutics, Inc gets an overall score of 1/5.